Skip Nav Destination
Issues
1 August 2013
-
Cover Image
Cover Image
Several genetic alterations of cancer cause increased expression of a key regulator of glucose metabolism, 6-phosphofructo-2-kinase (PFKFB3). A competitive inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was previously found to reduce both the glucose metabolism and proliferation of cancer cells. We report an optimized 3PO derivative in which a quinolinyl ring has been substituted for a pyridinyl ring, 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15), that is 100-fold more potent than 3PO. Computational modeling presented suggests that the higher activity of PFK15 relative to 3PO may be due to the lack of interaction of 3PO with amino acids that form the ADP/ATP binding site of PFKFB3 (highlighted in green). For details, see article by Clem and colleagues on page 1461. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Amy D. Guertin; Jing Li; Yaping Liu; Melissa S. Hurd; Alwin G. Schuller; Brian Long; Heather A. Hirsch; Igor Feldman; Yair Benita; Carlo Toniatti; Leigh Zawel; Stephen E. Fawell; D. Gary Gilliland; Stuart D. Shumway
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
K. Mark Parnell; Jason M. Foulks; Rebecca N. Nix; Adrianne Clifford; Jeremy Bullough; Bai Luo; Anna Senina; David Vollmer; Jihua Liu; Virgil McCarthy; Yong Xu; Michael Saunders; Xiao-Hui Liu; Scott Pearce; Kevin Wright; Marc O'Reilly; Michael V. McCullar; Koc-Kan Ho; Steven B. Kanner
Large Molecule Therapeutics
Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Caroline Rozan; Amélie Cornillon; Corinne Pétiard; Martine Chartier; Ghislaine Behar; Charlotte Boix; Brigitte Kerfelec; Bruno Robert; André Pèlegrin; Patrick Chames; Jean-Luc Teillaud; Daniel Baty
Cancer Therapeutics Insights
Genetic and Chemical Targeting of Epithelial-Restricted with Serine Box Reduces EGF Receptor and Potentiates the Efficacy of Afatinib
Manchao Zhang; Christopher E. Taylor; Longzhu Piao; Jharna Datta; Paul A. Bruno; Sanjay Bhave; Tizhi Su; James C. Lang; Xiujie Xie; Theodoros N. Teknos; Anna K. Mapp; Quintin Pan
Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
Tian Ma; Fabrizio Galimberti; Cherie P. Erkmen; Vincent Memoli; Fadzai Chinyengetere; Lorenzo Sempere; Jan H. Beumer; Bean N. Anyang; William Nugent; David Johnstone; Gregory J. Tsongalis; Jonathan M. Kurie; Hua Li; James DiRenzo; Yongli Guo; Sarah J. Freemantle; Konstantin H. Dragnev; Ethan Dmitrovsky
Efficacy of the Specific Endothelin A Receptor Antagonist Zibotentan (ZD4054) in Colorectal Cancer: A Preclinical Study
Samer-ul Haque; Michael R. Dashwood; Mohammed Heetun; Xu Shiwen; Noreen Farooqui; Bala Ramesh; Hazel Welch; Felicity J. Savage; Olagunju Ogunbiyi; David J. Abraham; Marilena Loizidou
Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Michaël Cerezo; Mélanie Tichet; Patricia Abbe; Mickaël Ohanna; Abdelali Lehraiki; Florian Rouaud; Maryline Allegra; Damien Giacchero; Philippe Bahadoran; Corine Bertolotto; Sophie Tartare-Deckert; Robert Ballotti; Stéphane Rocchi
Companion Diagnostics and Cancer Biomarkers
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.